Status of Ongoing Proceedings
For information on how to obtain public transcripts of proceedings, please contact the Registrar, Riaz Awadia, by phone at 613-288-9597 or by e-mail at Riaz.Awadia@pmprb-cepmb.gc.ca.
Dates of Upcoming Hearings or Pre-Hearing Conferences
| Case | Event | Date / Location |
|---|---|---|
| - | - | - |
Matters before the Board
Judicial Review of Board Decisions and Appeals
| Patented Drug Product | Indication / Use | Patentee | Issue | Date of Notice of Application | Status |
|---|---|---|---|---|---|
Soliris |
Paroxysmal Nocturnal Hemoglobinuria Atypical Hemolytic Uremic Syndrome |
Alexion Pharmaceuticals Inc. |
Allegations of excessive pricing |
January 20, 2015 |
Court File A-237-19 (RE Appeal of Federal Court’s decision in T-1596-17 RE Board Panel’s decision of Sept 20, 2017)
|
Differin |
Acne |
Galderma Canada Inc. |
Failure to file (jurisdiction) |
August 11, 2020 |
Court File T-906-20 (RE Board Panel’s decision of May 7, 2020)
|
Other Court Proceedings Relevant to the PMPRB
| Issue | Applicant | Respondent | Court | Status |
|---|---|---|---|---|
Vires of amendments to Patented Medicines Regulations |
Innovative Medicines Canada et al |
Attorney General of Canada |
Federal Court of Appeal |
Court File A-215-20 (Appeal of Federal Court’s decision in T-1465-19)
|
Constitutionality of ss 79-103 of the Patent Act and the Patented Medicines Regulations |
Merck Canada Inc et al |
Attorney General of Canada |
Court of Appeal of Quebec |
Court File TBD (Appeal of Superior Court of Quebec’s decision in 500-17-109270-192)
|
Vires of Guidelines issued by the PMPRB |
Innovative Medicines Canada et al |
Attorney General of Canada |
Federal Court |
Court File T-1419-20 (RE Board’s Decision to issue Guidelines on October 23, 2020)
|
Report a problem or mistake on this page
- Date modified: